Literature DB >> 11827431

Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development.

A D McCarthy1, S B Etcheverry, A M Cortizo.   

Abstract

In chronically uncompensated diabetes mellitus, an increase has been observed in the content of advanced glycation endproduct (AGE)-modified proteins in various tissues, including bone. This increase can lead to a local imbalance in the secretion of cytokines and growth factors, and has been implicated in the pathophysiology of the longterm complications of diabetes. We have previously shown that the proliferation and differentiation of UMR106 rat osteosarcoma and MC3T3E1 mouse calvaria-derived cell lines are regulated by AGE-modified proteins, possibly through the recognition of these AGEs by specific membrane-associated receptors. In the present study, we investigated the effects of AGE-proteins on the secretion of insulin-like growth factor-I (IGF-I) and its binding proteins (IGFBPs) by both osteoblast-like cell lines. In the case of MC3T3E1 cells, this was studied throughout their successive stages of development: proliferation, differentiation and mineralisation. For every condition, cells were incubated 24 hours with increasing concentrations of either bovine serum albumin (BSA) or AGE-BSA. IGF-I in conditioned media was separated from IGFBPs by acid gel filtration-centrifugation, and measured by radioimmunoassay. IGFBPs in conditioned media were analysed by a semi-quantitative western ligand blot. In UMR106 cells, low doses of AGE-BSA significantly decreased the secretion of both IGF-I (56% of control) and a 24 kDa IGFBP (80% of control). Results for MC3T3E1 cells, which predominantly secrete 29 kDa IGFBPs, were dependent on the stage of development. In proliferating preosteoblastic cells, AGE-BSA decreased the secretion of IGF-I (34%-37% of control) while increasing the secretion of IGFBP (124%-127% of control). On the other hand, secretion of these components of the IGF system by mature (differentiated) cells was unaffected by the presence of AGE-BSA. When these cells finally attained mineralisation, incubation with AGE-modified BSA provoked an increase both in IGFBP (131%-169% of control) and in IGF-I secretion (119%-123% of control). The presented evidence suggests that the modulation of growth and development by AGE-modified proteins, previously described for both cell lines, could be the result of an autocrine-paracrine mechanism involving the IGF-IGFBP system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11827431     DOI: 10.1007/s005920170007

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  24 in total

1.  Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK).

Authors:  Ana M Cortizo; María G Lettieri; Daniel A Barrio; Natalia Mercer; Susana B Etcheverry; Antonio D McCarthy
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

2.  Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells.

Authors:  Natalia Mercer; Hafiz Ahmed; Susana B Etcheverry; Gerardo R Vasta; Ana Maria Cortizo
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

3.  Bone fragility in type 2 diabetes mellitus.

Authors:  Toru Yamaguchi
Journal:  World J Orthop       Date:  2010-11-18

4.  Bone cells and bone turnover in diabetes mellitus.

Authors:  Mishaela R Rubin
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

5.  In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption.

Authors:  X Neil Dong; An Qin; Jiake Xu; Xiaodu Wang
Journal:  Bone       Date:  2011-04-21       Impact factor: 4.398

Review 6.  Contribution of RAGE axis activation to the association between metabolic syndrome and cancer.

Authors:  Ma Eugenia Garay-Sevilla; Armando Gomez-Ojeda; Ileana González; Claudia Luévano-Contreras; Armando Rojas
Journal:  Mol Cell Biochem       Date:  2021-01-04       Impact factor: 3.396

7.  Insulin Resistance and the IGF-I-Cortical Bone Relationship in Children Ages 9 to 13 Years.

Authors:  Joseph M Kindler; Norman K Pollock; Emma M Laing; Assaf Oshri; Nathan T Jenkins; Carlos M Isales; Mark W Hamrick; Ke-Hong Ding; Dorothy B Hausman; George P McCabe; Berdine R Martin; Kathleen M Hill Gallant; Stuart J Warden; Connie M Weaver; Munro Peacock; Richard D Lewis
Journal:  J Bone Miner Res       Date:  2017-07       Impact factor: 6.741

8.  Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus.

Authors:  I Kanazawa; T Yamaguchi; M Yamamoto; M Yamauchi; S Yano; T Sugimoto
Journal:  Osteoporos Int       Date:  2007-07-14       Impact factor: 4.507

Review 9.  Impact of Type 2 Diabetes Mellitus and Antidiabetic Medications on Bone Metabolism.

Authors:  Hae Sang Lee; Jin Soon Hwang
Journal:  Curr Diab Rep       Date:  2020-11-27       Impact factor: 4.810

Review 10.  The association between metabolic syndrome components and the development of atherosclerosis.

Authors:  Anahita Aboonabi; Roselyn Rose' Meyer; Indu Singh
Journal:  J Hum Hypertens       Date:  2019-10-21       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.